Recent Quotes (30 days)

You have no recent quotes
chg | %

T2 Biosystems Inc  

(Public, NASDAQ:TTOO)   Watch this stock  
Find more results for TTOO
3.98
-0.01 (-0.25%)
Real-time:   12:07PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.92 - 4.10
52 week 2.50 - 6.99
Open 3.96
Vol / Avg. 72,687.00/171,185.00
Mkt cap 142.58M
P/E     -
Div/yield     -
EPS -1.91
Shares 35.82M
Beta 1.40
Inst. own 60%
Feb 12, 2018
Q4 2017 T2 Biosystems Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 2, 2017
Q3 2017 T2 Biosystems Inc Earnings Call - Webcast
Nov 2, 2017
Q3 2017 T2 Biosystems Inc Earnings Release
Sep 25, 2017
T2 Biosystems Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 8, 2017
T2 Biosystems Inc at BioCentury NewsMakers in the Biotech Industry Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1270.40% -1343.23%
Operating margin -1122.47% -1247.01%
EBITD margin - -1190.64%
Return on average assets -84.61% -62.14%
Return on average equity -370.80% -127.04%
Employees 178 -
CDP Score - -

Address

101 Hartwell Ave
LEXINGTON, MA 02421-3125
United States - Map
+1-781-4571200 (Phone)
+1-781-3573080 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

Officers and directors

John McDonough President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Michael J. Cima Ph.D. Co-Founder, Independent Director
Age: 57
Bio & Compensation  - Reuters
Darlene Deptula-Hicks Chief Financial Officer, Senior Vice President, Treasurer
Age: 59
Bio & Compensation  - Reuters
Joanne Spadoro Ph.D. Chief Operations Officer
Age: 58
Bio & Compensation  - Reuters
Rahul K. Dhanda Senior Vice President - Corporate Development
Age: 44
Bio & Compensation  - Reuters
Thomas J. Lowery Ph.D. Chief Scientific Officer
Age: 38
Bio & Compensation  - Reuters
Michael Gibbs Vice President, General Counsel
Age: 46
Bio & Compensation  - Reuters
Michael A. Pfaller M.D. Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Seymour E. Liebman Director
Age: 68
Bio & Compensation  - Reuters
John W. Cumming Independent Director
Age: 71
Bio & Compensation  - Reuters